Opthotech soars in debut

|By:, SA News Editor

More from the world of healthcare-related IPOs: Opthotech (OPHT +18%) — they make Fovista, the Phase 3 wet AMD therapy — opens at $23.06 and moves higher.

Fovista is being developed as a combo treatment for use with anti-VEGF agents like Macugen (VRX), and Lucentis (RHHBY.OB, NVS).